Category: Media

Aurealis Pharma Announces 7.8MCHF Financing to Advance the Chronic Wound Lead Candidate AUP-16 to Diabetic Foot Ulcer Patients under New Brand Aurealis Therapeutics AG

Press release Basel Switzerland, Kuopio Finland – February 8th, 2019.Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The Company also confirmed the de-merger and a … Continued


Read more


Aurealis Pharma Submitted Clinical Trial Application for First-in-Human Phase 1-2A Clinical Study to German Health Authority Paul-Ehrlich-Institute (PEI)

Press Release Basel Switzerland, Kuopio Finland – October 15th, 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced today the successful submission of its first Clinical Trial Application to the German Health Authority Paul-Ehrlich-Institute (PEI) for the lead development candidate AUP1602-C to be studied in … Continued


Read more


Aurealis Pharma to Strengthen It´s Board of Directors by Appointing Mr. Iain Buchanan, a Seasoned Biotech and Pharma Industry Executive

Press Release Basel Switzerland, Kuopio Finland – May 22nd 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that Mr. Iain Buchanan has joined the board of directors of the company as of May 16th 2018. Existing board members CSO and founder Mr. … Continued


Read more


Aurealis Pharma To Present at the European Wound Management Association (EWMA) Congress 2018 in Krakow, Poland, May 9th – 11th 2018

Press Release Basel Switzerland, Kuopio Finland – April 30th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company´s progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at … Continued


Read more


Aurealis Pharma To Attend The Swiss Biotech Day in Basel, May 3rd 2018

Press Release Basel Switzerland, Kuopio Finland – April 26th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company´s progress at the Swiss Biotech Day in Basel on May 3rd … Continued


Read more


Aurealis Pharma To Present at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich, February 26-27th 2018

Press Release Basel Switzerland, Kuopio Finland – February 19th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on … Continued


Read more


Aurealis Pharma to Present at Swiss Nordic Bio 2018 in Zurich, February 8th 2018

Press Release Basel Switzerland, Kuopio Finland – February 6th 2018. Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018. … Continued


Read more